J&J's Erleada Shows Dramatic Efficacy in High-Risk Prostate Cancer Surgery Trial
核心洞察
Johnson & Johnson's Erleada combined with hormone therapy demonstrated nine-fold improvement in cancer elimination rates compared to hormone therapy alone in high-risk prostate cancer patients.
The combination treatment reduced risk of cancer spread or death by 20% in six-month regimens and 29% in full-year treatments over five years of follow-up.
Results from the 2,000-patient trial could transform treatment approaches for the 40% of U.S. prostate cancer patients classified as high-risk.
Johnson & Johnson's prostate cancer drug Erleada (apalutamide) demonstrated remarkable efficacy when combined with hormone-blocking therapy in treating high-risk localized prostate cancer, according to late-stage trial data presented at the American Society of Clinical Oncology meeting in Chicago. The study results could fundamentally change treatment approaches for men with high-risk prostate cancer who are candidates for surgical intervention.
Nine-Fold Improvement in Cancer Elimination
The five-year study followed patients who received Erleada with hormone-blocking therapy six months before and after prostate surgery. Patients receiving the combination regimen were nine times more likely to have little to no detectable cancer in the prostate at the time of surgery compared with those given testosterone-blocking therapy alone. Specifically, 8.9% of patients who received the combination treatment had minimal detectable cancer at surgery, compared with just 1% of those receiving hormone therapy alone.
The addition of Erleada also reduced the risk of cancer spreading or death by 20% in the six-month treatment group. For patients receiving a full year of combination therapy before and after surgery, the benefits were even more pronounced, with a 29% reduction in risk of recurrence and death.
Extended Treatment-Free Survival
Men who received the full-year combination therapy went more than six years on average before requiring subsequent treatment, nearly double the time compared to the hormone therapy alone group. This represents a significant improvement for patients, as nearly half of those who receive current standard prostate-removal surgery and radiation see their cancer return and require additional treatment.
Addressing Significant Unmet Need
The trial enrolled more than 2,000 patients with high-risk localized or locally advanced prostate cancer who were candidates for prostate gland removal surgery. This patient population represents approximately 40% of the 330,000 people diagnosed with prostate cancer annually in the United States, according to J&J data.
"No ARPIs are approved for localized high-risk prostate cancer with either surgery or radiation. So the (data) would be paradigm changing," said Dr. Mary-Ellen Taplin, the study's lead researcher from Dana-Farber Cancer Institute in Boston.
Mechanism and Safety Profile
Erleada belongs to a class of drugs called androgen receptor pathway inhibitors (ARPIs) that block signals driving prostate cancer growth. The drug works by inhibiting testosterone-driven cancer progression, complementing hormone therapy that suppresses testosterone production.
The safety profile of the Erleada combination treatment remained consistent with previous studies. Common side effects among patients included hot flushes, urinary incontinence, and erectile dysfunction. These adverse events align with the known safety profile of androgen receptor pathway inhibition.
Competitive Landscape and Regulatory Path
Widely used ARPIs in the prostate cancer treatment landscape include Pfizer's Xtandi and Bayer (搜索)'s Nubeqa. However, none are currently approved for localized high-risk prostate cancer treatment with surgery or radiation.
Erleada received U.S. approval in 2018 and is currently used in combination with hormone therapy for more advanced prostate cancer stages. Johnson & Johnson plans to work with regulators globally to expand approval for earlier-stage prostate cancer treatment based on these trial results.
"The patient benefit here is unequivocal," said Mark Wildgust, J&J's medical affairs lead for oncology. "I think that the evidence is really showing that Erleada is adding something that we had not seen before."
The data suggests a potential shift from the current standard of care, which primarily relies on surgery to remove the prostate and radiation therapy for high-risk localized or locally advanced prostate cancer patients.